Genentech, a Roche Group member, has received FDA approval for TNKase (tenecteplase) to treat acute ischemic stroke (AIS) in adults. This marks the company's second AIS treatment approval, reinforcing its leadership in stroke care alongside Activase (alteplase).
TNKase offers a simplified five-second IV bolus administration, compared to Activase, which requires an IV bolus followed by a 60-minute infusion. To support its new approval, Genentech plans to introduce a 25 mg vial configuration in the coming months.
Levi Garraway, M.D., Ph.D., Genentech's Chief Medical Officer, highlighted the approval as a major advancement in stroke treatment, emphasizing TNKase's faster and simpler administration, which is critical in acute stroke cases.
Stroke remains a leading cause of death and long-term disability in the U.S., affecting over 795,000 people annually. Immediate intervention is crucial, as AIS leads to rapid and irreversible brain damage.
The FDA's decision was based on the AcT trial, a large multi-center study demonstrating TNKase's comparable safety and efficacy to Activase. Conducted by the University of Calgary and funded by the Canadian Institute of Health Research, the study involved patients across 22 stroke centers in Canada.
TNKase is also FDA-approved for treating acute ST-elevation myocardial infarction (STEMI) in adults.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.